viewAnteris Technologies Ltd

Admedus appoints Simon Buckingham to board

Buckingham has more than 25 years’ experience in the global pharmaceutical industry.

Admedus has appointed Simon Buckingham to its board

Admedus (ASX:AHZ) has appointed Simon Buckingham to its board of directors as a non-executive director to replace outgoing Michael Bennett.

Buckingham has more than 25 years’ experience in the global pharmaceutical industry across a range of functions and a variety of therapeutic areas.

He is currently a senior global advisor to Actelion, one of the world’s leading biopharmaceutical companies, and is a director of Actelion Australia.

Buckingham is currently a non-executive director of Pharmaxis (ASX:PXS), a pharmaceutical research company with a portfolio including two respiratory products approved in various world markets and a research pipeline focused on areas of high unmet clinical need in inflammatory and fibrotic diseases.

He also sits on the boards of Creso Pharma (ASX:CPH) and Vaxxilon AG.

Wayne Paterson, chairman, commented: “Simon Buckingham brings to Admedus an extremely impressive depth of experience and a full spectrum of the most relevant qualifications.

“The board welcomes him to Admedus and looks forward to his insight and contribution as we continue the Company’s progress with growth and expansion.”

Quick facts: Anteris Technologies Ltd

Price: 4.08 AUD

Market: ASX
Market Cap: $24.11 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the...


Admedus CEO in New York to update on recent key milestones

Admedus Ltd (ASX:AHZ) CEO Wayne Paterson visited the Proactive Investors New York studio to update on key milestones the company has achieved in the past few months, including receiving European approval on two of its products.

on 03/17/2019

2 min read